ALYST Health, Premier Concierge Addiction Treatment Program, Adopts SOBRsafe Technology for Client Use
- None.
- None.
Insights
The integration of SOBRsafe's SOBRsure™ technology by ALYST Health represents a notable development in the healthcare and technology sectors, particularly within the addiction treatment market. The initial purchase of SOBRsure™ wristbands by ALYST not only signifies a direct revenue stream for SOBR Safe, Inc. but also suggests potential for recurring revenue through continuous demand for the wearable bands and associated services.
The adoption of such technology in healthcare settings aligns with broader industry trends towards remote patient monitoring and personalized healthcare solutions. By providing a non-invasive and privacy-respecting alternative to traditional alcohol monitoring methods, SOBRsafe is positioned to capture a niche market segment that values these attributes. This could lead to increased market share and customer loyalty, which are critical factors for long-term business sustainability and growth.
The accreditation by The Joint Commission underscores the credibility and potential efficacy of ALYST's at-home addiction treatment program, which could lead to increased adoption rates of the SOBRsure™ wearable band. From a medical research perspective, the use of transdermal alcohol detection technology offers a non-intrusive method for monitoring alcohol consumption, which could improve patient compliance and treatment outcomes.
Continuous monitoring through wearable technology also provides a wealth of data that could be invaluable for ongoing research into addiction patterns and treatment efficacy. Over time, the accumulation of such data may contribute to the refinement of addiction treatment protocols and the development of predictive analytics for relapse prevention.
For investors, the partnership between SOBR Safe, Inc. and ALYST Health could be a signal of SOBRsafe's commercial viability and scalability. The market's reaction to this news will likely hinge on the projected volume of sales, the potential for SOBRsafe to secure additional contracts with similar healthcare providers and the long-term cost savings associated with the use of wearable technology in addiction treatment.
While the initial purchase provides a positive outlook, the long-term financial impact will depend on the rate of adoption among ALYST's clientele and the potential expansion to other treatment programs. Investors should monitor the adoption rates and customer feedback, as these will be critical indicators of the product's performance and its impact on SOBR Safe, Inc.'s financial health.
Fully At-Home Alcohol Treatment Program to Offer SOBRsure™ Wearable Band as More Flexible, Humane Accountability Option
DENVER, CO / ACCESSWIRE / February 20, 2024 / SOBR Safe, Inc. (NASDAQ:SOBR) ("SOBRsafe"), providers of next-generation transdermal alcohol detection solutions, today announced that ALYST Health ("ALYST") is adopting the SOBRsafe™ technology for use in its concierge addiction treatment services, the first and only at-home addiction treatment program accredited by The Joint Commission - the nation's oldest and largest health care standards-setting body. ALYST has made an initial purchase of SOBRsure™ alcohol detection wristbands and is integrating them for client use.
"Conventional treatment centers - and conventional monitoring methods - aren't always a good fit for many people who value privacy, personalized treatment or their daily routine," stated ALYST Founder and CEO Richard Blair. "This is why we feel SOBRsure is an ideal addition to our program, which moves the point of care from the treatment center to the comfort and privacy of a client's home - without sacrificing quality. SOBRsure brings dignity and convenience to remote monitoring, and we believe it will further empower recovery success."
Followed SOBRsafe Chairman and CEO Dave Gandini, "We are honored to work with ALYST, a standard-bearer for behavioral health innovation. We both seek to optimize recovery outcomes by looking beyond the walls of traditional treatment."
---
About SOBRsafe™
Alcohol misuse is the fourth leading cause of preventable death in America, and the seventh worldwide. Yet prevention and monitoring solutions have not kept pace with this epidemic. Legacy technologies are invasive and inefficient, unhygienic and unconnected. There has to be a better way.
Enter SOBRsafe™. Our advanced transdermal (touch-based) technology detects and reports in real-time the presence of alcohol as emitted through a user's skin - no breath, blood or urine sample is required. With a powerful backend data platform, SOBRsafe provides next generation, passive detection technology for the behavioral health, judicial and consumer markets, and for licensing and integration.
The SOBRsafe technology is commercially available for access control (SOBRcheck), wearable use (SOBRsure) and licensing/white labeling. At SOBRsafe, we are creating a culture of prevention and support. To learn more, visit www.sobrsafe.com.
Contact SOBRsafe:
investor.relations@sobrsafe.com
Safe Harbor Statement
Our prospects here at SOBRsafe are subject to uncertainties and risks. This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business, and reflect our beliefs and assumptions based upon information available to us at the date of this press release. In some cases, you can identify these statements by words such as "if," "may," "might," "will, "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue," and other similar terms. These forward-looking statements include, among other things, plans for proposed operations, descriptions of our strategies, our product and market development plans, and other objectives, expectations and intentions, the trends we anticipate in our business and the markets in which we operate, and the competitive nature and anticipated growth of those markets. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors including, but not limited to, the risks and uncertainties discussed under risk factors in our registration statement on Form S-1, (File No. 333-267882) as well as our other filings with the SEC. We undertake no obligation to revise or update any forward-looking statement for any reason.
SOURCE: SOBR Safe, Inc.
View the original press release on accesswire.com
FAQ
What is the name of the company partnering with ALYST Health?
What technology is being adopted by ALYST Health for its addiction treatment services?
Which organization accredited ALYST Health's at-home addiction treatment program?
What product is ALYST Health integrating for client use?
Who is the Founder and CEO of ALYST Health?
Who is the Chairman and CEO of SOBR Safe, Inc.?
